Squarepoint’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-185,337
| Closed | -$6.21M | – | 4933 |
|
|
2026
Q1 | $6.21M | Sell |
185,337
-283,317
| -60% | -$11.1M | 0.01% | 1346 |
|
|
2025
Q4 | $21.7M | Buy |
468,654
+399,700
| +580% | +$21.9M | 0.02% | 703 |
|
|
2025
Q3 | $4.66M | Buy |
+68,954
| New | +$5.11M | ﹤0.01% | 1517 |
|
|
2024
Q2 | – | Sell |
-14,580
| Closed | -$624K | – | 4599 |
|
|
2024
Q1 | $624K | Buy |
14,580
+7,671
| +111% | +$347K | ﹤0.01% | 2897 |
|
|
2023
Q4 | $278K | Buy |
+6,909
| New | +$197K | ﹤0.01% | 3407 |
|
|
2021
Q1 | – | Sell |
-2,497
| Closed | -$72K | – | 3565 |
|
|
2020
Q4 | $72K | Sell |
2,497
-13,329
| -84% | -$385K | ﹤0.01% | 2767 |
|
|
2020
Q3 | $596K | Sell |
15,826
-3,390
| -18% | -$99.1K | 0.01% | 1299 |
|
|
2020
Q2 | $640K | Buy |
19,216
+16,470
| +600% | +$714K | 0.01% | 1169 |
|
|
2020
Q1 | $98K | Buy |
+2,746
| New | +$117K | ﹤0.01% | 1641 |
|
Squarepoint's SLNO Position: Q2 2026 in Review
Squarepoint sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 185,337 shares — an estimated $6.21M sold.
Squarepoint first reported a position in SLNO in Q1 2020 and held it in 9 quarters. The position peaked at $21.7M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Squarepoint reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Squarepoint sold 185,337 Soleno Therapeutics shares in Q2 2026, an estimated $6.21M.
- Squarepoint first reported a position in Soleno Therapeutics in Q1 2020 and held it in 9 quarters.
- Squarepoint's Soleno Therapeutics position peaked at $21.7M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.